Last updated: April 26, 2026
Who Supplies Veltassa (Patiromer) and What Do Their Roles Cover?
Veltassa is a branded, prescription treatment product for hyperkalemia. It is marketed in the U.S. by Vifor Pharma. The supply chain is a mix of (1) branded drug manufacturing and (2) contracted manufacturing for drug substance and/or finished dosage forms, with distribution handled through established pharma logistics channels.
How does Veltassa get supplied into pharma distribution?
Veltassa is supplied through standard branded-drug routes:
- Manufacturer-to-distributor channels for wholesale and hospital pharmacy systems
- Cold-chain is not a requirement based on routine handling expectations for oral solid products (no temperature-controlled logistics as a defining constraint is reported in labeling and common market practice)
- Pharmacist-facing availability is managed via national wholesale networks in the U.S. (3PL and WAC-based distribution)
Brand Manufacturer: Who markets and owns the product in-market?
Who is the market authorization holder / brand owner?
- Vifor Pharma is the U.S. marketer of Veltassa.
Evidence point: Veltassa prescribing information identifies the company marketing the drug in the U.S. and is the basis for assigning market responsibility in supplier mapping (manufacturer and label-holder roles are commonly distinct but both matter for procurement and compliance workflows). (See cited prescribing information in sources.)
Drug Supply: Who actually makes the tablets/powder?
Which companies act as suppliers for the finished drug product?
Finished-dose supply is typically produced by contract manufacturing organizations (CMOs) under controlled quality agreements. Public-facing “suppliers” for branded oral drugs are often not fully enumerated in labeling, and procurement workflows typically rely on distributor-led visibility plus supplier qualification documents held by the brand owner.
Available public anchoring from the U.S. label:
- The prescribing information provides the product identity and manufacturer information format expected for U.S. drugs but does not always provide a complete public list of all underlying substance and component suppliers.
- Supplier mapping in practice uses the label-listed manufacturer for the finished product (the firm responsible for GMP release) and then traces upstream via DMF/CMC disclosures, internal qualification, and contract documentation.
Upstream components: Who supplies ingredients (drug substance and excipients)?
What upstream categories typically appear in Veltassa supply sourcing?
Veltassa is an oral powder used with water. Upstream suppliers in pharmaceutical sourcing generally fall into:
- Drug substance (patiromer sorbitex calcium) production
- Polymer and ion-exchange material inputs (key raw material category)
- Excipients (powder formulation components and processing aids)
Public procurement databases often identify upstream suppliers only indirectly via:
- DMF holders for polymer and ion-exchange manufacturing steps
- Excipients sourced from large global ingredient suppliers with broad pharma supply
But the Veltassa prescribing information is the primary public control point for the finished product release entity.
What supplier information can be used for vendor qualification and procurement?
Which public documents define the “right supplier” for regulatory and sourcing decisions?
For vendor onboarding, procurement usually needs to pin at least:
- GMP-release manufacturer for the finished product (label-listed manufacturing information)
- Label-holder/brand owner for supply continuity, shortage management, and allocation communications
- Regulatory listing support (NDC product and label pack changes)
Evidence base: Veltassa’s prescribing information and related FDA labeling references supply the “official” product identity fields used in procurement audits and regulatory submissions. (See cited sources.)
Operational Supplier Map for Veltassa (Practical Use)
How to structure Veltassa supplier engagement
Use a two-tier model for business decisions:
-
Tier 1: Brand owner / in-market accountable entity
- Vifor Pharma (U.S. marketer)
-
Tier 2: GMP-release manufacturer for the finished product
- Label-listed manufacturer of Veltassa (the entity that GMP releases the packaged product to distribution channels)
Upstream raw material and drug-substance suppliers are typically determined through:
- Brand owner supplier disclosure
- DMF-linked documentation
- Qualification packages and audit reports obtained during onboarding
Market supply and allocation signals
What are the real-world supply dynamics suppliers watch?
For branded oral products like Veltassa, supplier risk monitoring centers on:
- Batch release timing (GMP-release delays)
- Contracted CMO capacity utilization
- Raw material availability for ion-exchange polymer production and powder formulation inputs
For a supplier evaluation, the decision-grade metrics are:
- Distribution continuity via major wholesalers
- Allocation patterns during shortages
- Consistency in label pack and manufacturing site continuity
(These are operational signals, not items listed in the prescribing information.)
Key Takeaways
- Vifor Pharma is the U.S. marketer of Veltassa (patiromer) and is the main accountable supplier entity for in-market coordination.
- The GMP-release manufacturer of the finished product is the label-listed manufacturing entity in the prescribing information and is the supplier target for procurement-grade qualification.
- Upstream drug-substance and excipient suppliers are generally not fully enumerated in public labeling; they are identified through DMF-linked documentation and brand owner qualification packages tied to GMP release.
FAQs
1) Is Veltassa supplied by a single manufacturer or multiple suppliers?
Branded drugs typically involve at least two layers: the brand owner (in-market accountable entity) and the GMP-release manufacturer for finished product. Upstream raw material and drug-substance sourcing usually involves additional suppliers.
2) Can I use the prescribing information to identify the finished-product manufacturer?
Yes. The prescribing information is the authoritative public artifact for the finished product’s official manufacturing information used for regulatory and procurement mapping.
3) Who should be contacted for supply continuity or allocation issues?
The U.S. marketer/brand owner identified in the Veltassa prescribing information is the operational starting point for supply continuity.
4) Are drug-substance and excipient suppliers named on the label?
They are often not fully enumerated in the label. Vendor identification for upstream ingredients is usually handled via DMF and qualification documentation rather than public label text.
5) Does Veltassa require special storage conditions that affect supplier logistics?
For Veltassa, the storage expectations align with standard handling for oral solid dosage forms as reflected in label instructions and common distribution practice; cold-chain is not a defining feature.
References
[1] Veltassa (patiromer) prescribing information. FDA label access. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] Veltassa (patiromer) product labeling and NDC-related FDA documents. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
